New York Life Investment Management’s Atea Pharmaceuticals AVIR Stock Holding History

New York Life Investment Management’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-103,087	Closed	-$314K	–	1347
2023 Q4	$314K	Sell	103,087 -3,194	-3%	-$9.67K	﹤0.01%	1187
2023 Q3	$319K	Sell	106,281 -16,744	-14%	-$57K	﹤0.01%	1094
2023 Q2	$460K	Sell	123,025 -22,334	-15%	-$83.6K	﹤0.01%	787
2023 Q1	$487K	Buy	145,359 +66,796	+85%	+$271K	0.01%	763
2022 Q4	$378K	Buy	78,563 +8,850	+13%	+$44.8K	﹤0.01%	1066
2022 Q3	$397K	Buy	69,713 +5,123	+8%	+$39.2K	﹤0.01%	949
2022 Q2	$459K	Buy	+64,590	New	+$441K	0.01%	771

Other funds holding AVIR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

New York Life Investment Management's AVIR Position: Q1 2024 in Review

New York Life Investment Management sold out of Atea Pharmaceuticals (AVIR) in Q1 2024, closing a stake of 103,087 shares — an estimated $314K sold.

New York Life Investment Management first reported a position in AVIR in Q2 2022 and held it in 7 quarters. The position peaked at $487K in Q1 2023. 113 funds tracked by Wall St. Rank hold AVIR as of Q1 2024.

New York Life Investment Management reported no remaining Atea Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
New York Life Investment Management sold 103,087 Atea Pharmaceuticals shares in Q1 2024, an estimated $314K.
New York Life Investment Management first reported a position in Atea Pharmaceuticals in Q2 2022 and held it in 7 quarters.
New York Life Investment Management's Atea Pharmaceuticals position peaked at $487K in Q1 2023.
113 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2024.

Based on New York Life Investment Management's 13F filing for Q1 2024, filed 6 May 2024.